The safety and efficacy of MEK blocking agents in MM have been confirmed in an ongoing phase 2 study where 20% NRAS-mutated melanoma patients showed partial response to MEK inhibitor binimetinib with tolerated and manageable adverse events (140). This evidence concerns the gene MAP2K7 and melanoma.